Pharmaceutical returns have never been simple, but the rules that govern them are becoming more complicated each year. What once relied on a relatively small set of manufacturer guidelines has expanded into a patchwork of policies that vary by product, timing and eligibility.
Recent returns data shared by Inmar in the 96th edition of the HDA Factbook, and discussed during a November 2025 industry webinar, shows just how quickly this complexity is growing. The number of national pharmaceutical return policies continues to rise, with more customization at the product and lot level. At the same time, restrictions around partial returns, authorization and expiration windows are becoming more common.
As these rules evolve, pharmacies face a higher risk of missed credits, processing delays and compliance challenges. Understanding why returns policies are changing—and how those changes affect daily operations—is an important step toward managing returns more effectively.
Returns Policies Reflect Business Strategy
Returns policies are not static rules. They reflect manufacturer business strategies, regulatory expectations and supply chain realities. As these forces evolve, policies change with them.
In 2024, there were more than 12,400 national pharmaceutical return policies, an increase of more than 700 compared with the prior year. Many of these policies are no longer broad or standardized. Instead, they are increasingly customized at the National Drug Code (NDC) level and, in some cases, even at the lot level.
This level of customization makes it harder for pharmacies to rely on general rules of thumb. A product that is eligible for credit under one policy may be excluded under another, even if it appears similar on the surface.
More Rules, Narrower Margins for Error
As returns policies grow more detailed, the margin for error shrinks.
Data from the webinar shows several policy trends that increase complexity:
- A growing percentage of policies do not allow partial returns
- More policies explicitly do not authorize returns at all
- Prescription bottles are generally excluded from returns, except in recall situations
Each of these rules adds another decision point to the returns process. Missing one detail—such as whether a partial package is allowed—can turn a creditable return into uncreditable waste.
Expiration Windows Are Expanding—and Shifting
Expiration-based eligibility is another area where policies are becoming more nuanced.
Manufacturers are expanding the windows during which products may be eligible for credit, both before and after expiration. While this can increase potential recovery, it also adds complexity. Different products may have different eligibility windows, and those windows may change over time.
This shift places more pressure on timing and tracking. Products returned too early or too late may fall outside eligibility windows, even if they appear close to expiration.
Policy Complexity Increases Compliance Risk
Returns policies do not exist in isolation. They intersect with regulatory expectations around documentation, traceability and audit readiness.
As policies become more detailed, pharmacies must ensure that return decisions are properly documented and aligned with both manufacturer requirements and regulatory standards. Inconsistent or manual processes increase the risk of errors that may surface during audits or inspections.
The challenge is not just knowing the rules, but applying them consistently across locations, staff and inventory types.
Manual Processes Struggle to Keep Up
Many pharmacies still rely on manual or semi-manual processes to manage returns. These approaches may have worked when policies were simpler and more uniform. Today, they are increasingly strained.
Manually tracking policy changes, eligibility windows and documentation requirements is time-consuming and prone to error. As policy volume grows, so does the administrative burden on pharmacy staff—often pulling attention away from patient care and other critical tasks.
Why Policy Complexity Matters Financially
Policy complexity does not just affect compliance. It directly impacts financial performance.
When returns are mishandled due to policy misunderstandings:
- Credit opportunities are missed
- Processing timelines are extended
- Uncreditable waste increases
As seen in the returns data, the percentage of returns eligible for credit is rising. This makes accurate policy adherence even more important. The cost of getting it wrong grows as the value of returns increases.
Turning Complexity Into a Manageable Process
While returns policies are unlikely to become simpler, they can become more manageable.
Pharmacies that take a structured, data-driven approach to returns are better positioned to adapt to policy changes. This includes maintaining visibility into eligibility rules, standardizing workflows and reducing reliance on individual judgment calls.
The goal is not to memorize thousands of policies, but to build processes that help apply them accurately and consistently.
A New Reality for Returns Management
The growing complexity of pharmaceutical returns policies reflects broader changes across the healthcare supply chain. Customization, data-driven decision-making and tighter controls are becoming the norm.
For pharmacies, acknowledging this shift is an important first step. Returns are no longer governed by a short list of general rules. They require ongoing attention, reliable processes and the ability to adapt as policies evolve.
Understanding how and why policies are changing helps pharmacies reduce risk, protect revenue and approach returns with greater confidence.
Optimize your pharmacy returns process